DNA ¶Ç´Â RNAÀÇ »ýü ³» ¹ßÇöÀ» ÅëÇÑ º¤ÅÍÈ­ Ç×ü : ¾÷°è °üÁ¡¿¡¼­ º» °æÀï ºñÁî´Ï½º, ÀÌÇØ°ü°èÀÚ, ±â¼ú ¹× ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Vectorized Antibodies by In Vivo Expression of DNA or RNA: A Competitive Business, Stakeholder, Technology and Pipeline Analysis from an Industry Perspective
»óǰÄÚµå : 1759020
¸®¼­Ä¡»ç : La Merie Publishing
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
EUR 2,600 £Ü 4,213,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
EUR 5,200 £Ü 8,427,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
EUR 7,800 £Ü 12,640,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

º» º¸°í¼­¿¡¼­´Â DNA ¶Ç´Â RNAÀÇ »ýü ³» ¹ßÇö¿¡ ÀÇÇÑ º¤ÅÍÈ­ Ç×ü °³¹ß ÀÌÇØ°ü°èÀÚ, ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ, ½Å¾à Èĺ¸¹°Áú ÇÁ·ÎÆÄÀϰú ±¸¼º, 2025³â 6¿ù ÇöÀç ¾÷°è »óȲÀ¸·Î º» ºñÁî´Ï½º °Å·¡¿¡ ´ëÇÑ ÇØ¼³°ú ºÐ¼®À» ¼ö·ÏÇß½À´Ï´Ù.

ÁÖ·Î Æ÷À¯·ù ¼¼Æ÷ ¹è¾ç ½Ã½ºÅÛ¿¡¼­ »ýü ¿Ü¿¡¼­ »ý»êµÈ ´ÜÀÏŬ·ÐÇ×ü¸¦ ÀÌ¿ëÇÑ ¼öµ¿Àû ¸é¿ª¿ä¹ýÀº Áö³­ 30³â µ¿¾È ÀÓ»óÀûÀ¸·Î³ª »ó¾÷ÀûÀ¸·Î ¼º°øÀûÀÎ Ä¡·á¹ýÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. Ä¡·á¿ë Ç×üÀÇ ÀÓ»óÀû ¼º°ø¿¡µµ ºÒ±¸Çϰí, Á¦Á¶ ¹× °ü¸®¿¡ µû¸¥ ³ôÀº ºñ¿ë°ú °í¿ë·® ¹Ýº¹ Åõ¿©¿¡ ÇÊ¿äÇÑ ¾à¹°ÀÇ ¾ç µî ¿©ÀüÈ÷ ÇѰ谡 ÀÖ½À´Ï´Ù. Á¦Á¶ °øÁ¤ÀÇ °³¹ß»Ó¸¸ ¾Æ´Ï¶ó ´ë·®ÀÇ Ç×ü¸¦ »ó¾÷Àû ±Ô¸ð·Î GMP Á¦Á¶ÇÏ´Â °ÍÀº º¹ÀâÇÑ °úÁ¤ÀÔ´Ï´Ù. ¶ÇÇÑ, ¸¸Á·½º·¯¿î ¾àµ¿ÇÐÀû ÇÁ·ÎÆÄÀÏÀ» ¾òÁö ¸øÇϰí, ¾È±¸ Åõ¿©(¸Á¸·ÇÏ ÁÖ»ç µî)³ª ÁßÃ߽Űæ°è Åõ¿©(Ä«Å×ÅÍ »ðÀÔÀ» ÅëÇÑ Ã´¼ö°­ ³» ÁÖÀÔ µî)°¡ ¾î·Æ°Å³ª, ¾Ï Ä¡·á¿¡ ÀÖ¾î Áß¿äÇÑ Á¶Á÷ ƯÀ̼ºÀÌ ¾ø¾î Àü½Å Åõ¿©¿¡ µû¸¥ ºÎÀÛ¿ë°ú Á¦ÇÑÀûÀÎ È¿°ú¸¸ ¾òÀ» ¼ö ÀÖ´Â µî ºó¹øÇÑ Åõ¿©¿¡ µû¸¥ ºÒÆíÇÔÀÌ ÀÖ½À´Ï´Ù. ºÒÆíÇÔÀÌ ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ½À´Ï´Ù.

º¤ÅÍÈ­ Ç×ü´Â ÀÌ·¯ÇÑ ÇѰ踦 ±Øº¹ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÇ¸ç, DNA ¹× RNA ±â¼ú ±â¾÷¿¡°Ô´Â ÇöÀç À¯ÀüÀÚ Ä¡·áÁ¦°¡ ½ÂÀεǾú°Å³ª °³¹ß ÁßÀÎ Èñ±ÍÁúȯ ÀûÀÀÁõ¿¡ ºñÇØ ´õ Å« ½ÃÀå¿¡ ÁøÀÔÇÒ ¼ö ÀÖ´Â ÁÁÀº ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

DNA ¶Ç´Â RNA¿¡ ÀÇÇÑ Ä¡·á¿ë Ç×üÀÇ »ýü ³» ¹ßÇöÀº ±âÁ¸ Ç×ü Ä¡·áÀÇ ÇѰ踦 ÀϺγª¸¶ ±Øº¹ÇÒ ¼ö ÀÖ½À´Ï´Ù. Ç×ü µµÀÔ À¯ÀüÀÚ´Â ¹ÙÀÌ·¯½º º¤ÅÍ, Çö󽺹̵å DNAÀÇ ±ÙÀ° Á÷Á¢ ÁÖÀÔ, Àü±â õ°ø ¶Ç´Â Àü½Å Åõ¿©¿ë ÁöÁú ³ª³ëÀÔÀÚ¿Í °°Àº ºÐÀÚ Á¦Á¦¸¦ ÅëÇØ µµÀÔÇÒ ¼ö ÀÖ½À´Ï´Ù.

¾È°ú ÁúȯÀº ¹ÙÀÌ·¯½º DNA¿¡ ÀÇÇØ »ýü ³»¿¡¼­ ¹ßÇöµÇ´Â º¤ÅÍÈ­ Ç×üÀÇ ÁÖ¿ä ÀûÀÀÁõÀÔ´Ï´Ù. ½À¼º AMD Ä¡·á¿¡ ´ëÇÑ ´Ù¾çÇÑ Ç×VEGF º¤ÅÍÈ­ ÇÁ·Î±×·¥ÀÇ 1»ó ¹× 2»ó ÀÓ»ó½ÃÇè °á°ú´Â ¾ÈÀü¼º°ú ³»¾à¼º, ½Ã·Â ¹× ¸Á¸·µÎ²² °³¼±¿¡ ´ëÇÑ ¾ÈÁ¤¼º, ±×¸®°í4³â±îÁö Àå±â°£ Áö¼ÓµÇ´Â Ä¡·á È¿°ú¸¦ ÀÔÁõÇß½À´Ï´Ù. µÎ °³ÀÇ ¼­·Î ´Ù¸¥ Ç×-VEGF º¤ÅÍÈ­ Ç×ü°¡ ÀÓ»ó 3»ó¿¡¼­ °æÀïÇϰí ÀÖ½À´Ï´Ù. ù ¹øÂ° Ç×-VEGF º¤ÅÍÈ­ Ç×ü·ÎºÎÅÍÀÇ Å¾¶óÀÎ °á°ú´Â 2026³âÀ¸·Î ¿¹»óµÇ¸ç, ÇϳªÀÇ º¤ÅÍÈ­ Ç×ü ±â¼ú¿¡ ´ëÇÑ ÀÓ»óÀû °ËÁõÀ» Á¦°øÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â ´ÙÀ½°ú °°Àº ÃֽŠÁ¤º¸¿Í ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

Á¶»ç ¹æ¹ý:

º» º¸°í¼­´Â DNA ¶Ç´Â RNA »ýü ³» ¹ßÇöÀ» ÅëÇÑ º¤ÅÍÈ­ Ç×ü ºÐ¾ßÀÇ Á¦¾à ¹× ±â¼ú ±â¾÷ÀÇ ¿¬±¸°³¹ß ¹× Á¦ÈÞ È°µ¿À» Á¾ÇÕÀûÀ¸·Î °³°üÇÏ¿© º¤ÅÍÈ­ Ç×üÀÇ ¿¬±¸°³¹ß ¹× Á¦ÈÞ È°µ¿À» Æò°¡Çß½À´Ï´Ù. º» º¸°í¼­´Â ¹ÙÀÌ¿À Á¦¾à»ç ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷À» Æ÷ÇÔÇÑ ±â¾÷ ÀÌÇØ°ü°èÀÚÀÇ ½Äº°°ú ¼³¸íÀ» ¹ÙÅÁÀ¸·Î ÀÛ¼ºµÇ¾ú½À´Ï´Ù. ¸ðµç °ø°³ Á¤º¸´Â190À§ÀÇ °úÇÐÀû ¹®Çå(ÃÊ·Ï, Æ÷½ºÅÍ, ÇÁ·¹Á¨Å×À̼Ç, Àüü ³í¹®) ¶Ç´Â º¸µµÀÚ·á, ±â¾÷ ÇÁ·¹Á¨Å×À̼Ç, ¿¬Â÷º¸°í¼­, SEC °ø½Ã, ȨÆäÀÌÁö ÄÁÅÙÃ÷ µîÀÇ Ãâó·Î ¿¬°áµÇ´Â ÇÏÀÌÆÛ¸µÅ©·Î ¿ÏÀüÈ÷ ÂüÁ¶µÇ¾î ÀÖ½À´Ï´Ù.

°ü·Ã ±â¾÷

  • 4D Molecular Therapeutics
  • AbbVie
  • Accesion Therapeutics
  • Adverum Biotechnologies
  • Aegis Life
  • Akamis Bio
  • AstraZeneca
  • Avirmax Biopharma
  • Be Biopharma
  • BioInvent
  • BiomEdit
  • BioNTech
  • Capsida Biotherapeutics
  • Ceva Sante Animale(Ceva Animal Health)
  • Charles River
  • Chengdu Kanghong Pharmaceutical Group
  • Chengdu Origen Biotechnology
  • China Resource Biopharma(CRBio)
  • China Resource Biopharma(CRBio)
  • Clearside Biomedical
  • Criya Therapeutics
  • De novo Biotherapeutics
  • Entos Pharmaceuticals
  • Frontera Therapeutics
  • Hopewell Therapeutics
  • Ikarovec
  • I-Mab
  • Immorna
  • ImmVira
  • Inovio Pharmaceuticals
  • Levatio
  • MeiraGTx Holdings
  • METiS Pharmaceuticals & METiS Therapeutics
  • Multiverse Pharma
  • Nanite
  • Neuracle Genetics
  • NuclixBio
  • Otsuka Pharmaceutical Co
  • PharmAbcine
  • PharmAbs
  • ProBio
  • Promab Biotechnologies
  • PulseSight Therapeutics(Eyevensys)
  • Rampart Bioscience
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • RenBio
  • Reyon Pharmaceutical
  • Ring Therapeutics
  • RNAimmune
  • Sail Biomedicines
  • Scout Bio
  • Shanghai Pharmaceuticals Holding
  • Shape Therapeutics
  • Shattuck Labs
  • Skyline Therapeutics
  • ST Pharm
  • Suzhou Abogen Biosciences
  • Transgene
  • Vanotech
  • Vernagen
  • Vironexis Biotherapeutics
  • Xiamen Amoytop Biotech
  • Xuanzhu Biopharma

¸ñÂ÷

ºó¹øÇÑ ¾à¾î

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­·Ð

Á¦3Àå ÀÌÇØ°ü°èÀÚ ºÐ¼®

Á¦4Àå º¤ÅÍÈ­ Ç×ü ±â¼ú ÀÌÇØ°ü°èÀÚ °³¿ä

Á¦5Àå º¤ÅÍÈ­ Ç×ü ±â¼ú ºÐ¼®

Á¦6Àå º¤ÅÍÈ­ Ç×ü ±â¼ú °³¿ä

Á¦7Àå Ç×üÀÇ »ýü ³» ¹ßÇöÀ» À§ÇÑ ÆÄÀÌÇÁ¶óÀÎ ¹× Á¦Ç° Èĺ¸ ºÐ¼®

Á¦8Àå º¤ÅÍÈ­ Ç×ü Á¦Ç° Èĺ¸ °³¿ä

Á¦9Àå Âü°í ¹®Çå

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

This report provides you with a landscape description and analysis of Vectorized antibodies by in vivo expression of DNA or RNA regarding stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective as of June 2025.

Passive immunotherapy with monoclonal antibodies produced ex vivo mostly in mammalian cell culture systems has become a clinically and commercially successful treatment modality during the last three decades. Despite the clinical success of therapeutic antibodies, they still have limitations including the high cost, caused in great part by manufacturing and control, and the amount of drug needed for repeated administrations at high doses. Development of the manufacturing process as well as commercial scale GMP manufacturing of antibodies in great amounts is a complex process. Other limitiations refer to the inconvenience of frequent administrations associated with an unsatisfactory pharmacokinetic profile, challenging administration procedures to the eye (e.g. subretinal injection) or the central nervous system (e.g. intrathecal infusion with indwelling catheter) or side effects and limited efficacy upon systemic administration without tissue specificity, an important aspect in cancer therapy.

Vectorized antibodies hold promise to overcome many of these limitations and provide a great opportunity for DNA and RNA technology companies to enter larger markets compared with the rare disease indications for which current gene therapies are approved or in development.

In vivo expression of therapeutics antibodies by DNA or RNA may overcome at least some of the limitations of conventional antibody therapy. The antibody transgene may be delivered by viral vectors, by direct injection of plasmid DNA into the muscle followed by electroporation or by molecular formulations, such as lipid nanoparticles, for systemic administration.

Ophthalmic diseases are the lead indication for vectorized antibodies expressed in vivo by viral DNA. Clinical results from phase I and II clinical studies of various anti-VEGF vectorized programs for treatment of wet AMD demonstrated safety and tolerability and stable to improved vision and retinal thickness as well as long-term, durable treatment effects up to 4 years. Three distinct anti-VEGF vectorized antibodies are competing in clinical phase III. Topline results from the first anti-VEGF vectorized antibody are expected in 2026 and may provide clinical validation of one vectorized antibody technology.

The report brings you up-to-date with information about and analysis of:

Methodology:

This report evaluates the industry landscape of vectorized antibodies in research and development. The report provides a comprehensive overview of the R&D and partnering activities of pharmaceutical and technology companies in the field of vectorized antibodies by in vivo expression of DNA or RNA. This report is based on the identification and description of corporate stakeholders including biopharmaceutical companies and biotechnology companies. All publicly available information is fully referenced, either with more than 190 scientific references (abstracts, posters, presentations, full paper) or hyperlinks leading to the source of information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.

Who will benefit from the report?

Related Companies:

  • 4D Molecular Therapeutics
  • AbbVie
  • Accesion Therapeutics
  • Adverum Biotechnologies
  • Aegis Life
  • Akamis Bio
  • AstraZeneca
  • Avirmax Biopharma
  • Be Biopharma
  • BioInvent
  • BiomEdit
  • BioNTech
  • Capsida Biotherapeutics
  • Ceva Sante Animale (Ceva Animal Health)
  • Charles River
  • Chengdu Kanghong Pharmaceutical Group
  • Chengdu Origen Biotechnology
  • China Resource Biopharma (CRBio)
  • China Resource Biopharma (CRBio)
  • Clearside Biomedical
  • Criya Therapeutics
  • De novo Biotherapeutics
  • Entos Pharmaceuticals
  • Frontera Therapeutics
  • Hopewell Therapeutics
  • Ikarovec
  • I-Mab
  • Immorna
  • ImmVira
  • Inovio Pharmaceuticals
  • Levatio
  • MeiraGTx Holdings
  • METiS Pharmaceuticals & METiS Therapeutics
  • Multiverse Pharma
  • Nanite
  • Neuracle Genetics
  • NuclixBio
  • Otsuka Pharmaceutical Co
  • PharmAbcine
  • PharmAbs
  • ProBio
  • Promab Biotechnologies
  • PulseSight Therapeutics (Eyevensys)
  • Rampart Bioscience
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • RenBio
  • Reyon Pharmaceutical
  • Ring Therapeutics
  • RNAimmune
  • Sail Biomedicines
  • Scout Bio
  • Shanghai Pharmaceuticals Holding
  • Shape Therapeutics
  • Shattuck Labs
  • Skyline Therapeutics
  • ST Pharm
  • Suzhou Abogen Biosciences
  • Transgene
  • Vanotech
  • Vernagen
  • Vironexis Biotherapeutics
  • Xiamen Amoytop Biotech
  • Xuanzhu Biopharma

Table of Contents

Frequent Abbreviations

1. Executive Summary

2. Introduction

3. Stakeholder Analysis

4. Profiles of Stakeholders in Vectorized Antibody Technologies

5. Analysis of Vectorized Antibody Technologies

6. Profiles of Vectorized Antibody Technologies

7. Analysis of Pipeline and Product Candidates for in vivo Expression of Antibodies

8. Profiles of Vectorized Antibody Product Candidates

9. References

Figures & Tables

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â